Ainos-Aktie sets for 52-Wochen-Tief of 0.45 US-Dollar From Investing.com

In a year that Ainos Inc. was carried out, the biotechnology company has fallen from US$0.45 in about 52 weeks. This young price position reflects a steep slope of new developments and shows a significant change in the year of -84.48%. If you have started the investment, the action has fallen firmly and in the pasts of the Monaten quickly came from the Sechstel to the best results. If you are engaged in a meditative and special health care, it is a fact that the interests of the Obstacles are opposed to each other, the market performance is getting better and better.

In others, Ainos Inc. established a new company with the exclusive patent rights of the Taiwan Carbon Nano Technology Corporation (TCNT) for a Stickstoff-Sauerstoff-Trennmaschine for medical applications. This Vereinbarung is the part of the launched Bemühungen von Ainos, its product portfolio in the pharmaceutical and medical technology area of ​​erweitern. The Department Unternehmen has set up the company’s insurance company for the next Aktienprämien and the Ernennung of KCCW Accountancy Corp. zum an affiliated registered Wirtschaftsprüfungsunternehmen ratifiziert. Darüber has acquired Ainos Inc. granted a patent in Taiwan for its antiviral drug VELDONA®, which enables its treatment and prevention of coronavirus infections.

The AI ​​Nose Technology of the Unternehmens hat in Japanese Halbleiterfabriken a Genauigkeitsrate of 79% at the Identification-flüchtigere Verbindungen erreicht. There are strategic exclusive licenses for 10 Erfindungspatente from Taiwan Carbon Nano Technology worth 5.4 million US dollars, an AI Nose and Point-of-Care testing technology have been proven. The U.S. FDA has granted orphan drug status to VELDONA®, the oral interferon drug from Ainos, for the treatment of oral care in HIV-positive patients. A clinical trial begins at National Taiwan University Hospital.

Allerdings are planning to remove a possible delisting from the Nasdaq, the activities are carried out under the inherit orderlichen Mindestangebotspreis that have fallen. The Unternehmen have a Gnadenfrist until 13.01.2025, um the Compliance wiederherzustellen. The development of the business at Ainos Inc. has come to an end.

InvestingPro Acknowledgment

InvestingPro’s active market data is one of the best financial views of Ainos Inc. and the best results of the article funded by the companies. I showed a quarter of the turnover of nur 0.07 million US dollars a dramatic increase of 97.73% in the overview of the previous development. The strong character of the people is no longer focused on the talents of the people, thus developing and generating the market position.

InvestingPro-Tipps have said that it was “quickly profitable” and “in the end, there is no profitable war”, the article was significant. The Kurs-Buchwert-Verhältnis des Unternehmens von 0,18 deutet darauf hi, dass der Markt Ainos mit weniger als een Fünftel seines Buchwertes bewertet, was an erhebliche Skepticism of Investors who were focused on the Zukunft-saussichten of the Unternehmens Hinweist.

This email is lovely along with the text of the article that has tracked an 84.15% share price in a year. Before making any of the following analyses, InvestingPro offers 7 other tips, the following shed light on the financial capital and market position of companies that could benefit.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.